Highlights Savara Inc.

Stocks

SVRA

US8051111016

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 17:09:10 10/06/2026 BST			5-day change	1st Jan Change
5.140 ^USD	+4.26%		-1.52%	-14.26%

06-08	Savara Inc. Announces CFO Changes	CI
06-08	Savara Inc. Announces Step Down of Dave Lowrance as Chief Administrative Officer, Effective July 15, 2026	CI

Highlights

05-18	Savara Inc Announces New Exercise Capacity Data From The IMPALA-2 Phase 3 Clinical Trial Of Molgramostim Inhalation Solution In Autoimmune Pulmonary Alveolar Proteinosis	CI
05-12	Savara Q1 Loss Widens	MT
05-12	Earnings Flash (SVRA) Savara Posts Q1 Per Share Loss $-0.15, vs. FactSet Est of $-0.13 Loss	MT
05-12	Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-15	Savara Announces the U.S. Food & Drug Administration Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application in Autoimmune Pulmonary Alveolar Proteinosis	CI
04-07	Savara Inc. Announces MHRA Accepts Molbreevi Marketing Authorisation Application for Autoimmune PAP	CI
04-07	Savara announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted the Molbreevi* marketing authorisation application (MAA) for autoimmune pulmonary alveolar proteinosis (autoimmune PAP)	RE
03-30	Savara Says EMA Validates Marketing Authorization Application for Molbreevi to Treat Lung Disease	MT
03-30	Savara Inc. Announces Validation Of Marketing Authorization Application For Molbreevi In Autoimmune Pulmonary Alveolar Proteinosis	CI
03-13	Savara Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025	CI
03-13	Savara Q4 Loss Unchanged From Year Earlier	MT
03-13	Savara Inc Enters into Agreement of Lease for New Headquarters	CI
03-13	Earnings Flash (SVRA) Savara Posts Q4 Loss $0.13 a Share, vs. FactSet Est of $0.12 Loss	MT
03-06	Savara Says FDA Letter Indicates No Advisory Committee Meeting Planned for Molbreevi Application	MT
03-06	Savara Inc Provides Regulatory Update on the Molbreevi Development Program in Autoimmune Pulmonary Alveolar Proteinosis	CI
02-20	Savara Inc. Announces U.S. Food and Drug Administration Filed the MOLBREEVI Biologics License Application in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)	CI
01-08	Savara Inc. Announces an Exclusive Distribution Agreement for MOLBREEVI	CI
12-22	Savara resubmits the Biologics License Application to the U.S. Food and Drug Administration for Molbreevi	RE
12-22	Savara Inc. Resubmits the Biologics License Application to the U.S. Food and Drug Administration for Molbreevi for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis	CI
12-11	Savara Inc. Announces European Patent Office Intends to Grant A Patent for the Liquid Formulation of MOLBREEVI	CI
12-02	Savara, PARI Granted European Patent Covering Drug-Device Combination	MT
11-12	Savara Q3 net loss widens	RE
11-12	Savara Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
31/10/25	Savara Closes $149.5 Million Public Offering	MT
30/10/25	Savara announces pricing of public offering at $4.20 per share	RE